ADA editors ejected in New Orleans after distributing Diabetes Care reprints

Five leading scientists say they were physically forced out of the annual meeting of the American Diabetes Association (ADA) in New Orleans on Friday after distributing reprints of a recent journal editorial. The names at the center of the uproar include Steven Kahn, professor of medicine at the University of Washington and editor-in-chief of Diabetes Care, and former ADA president Desmond Schatz of the University of Florida, Gainesville. They were joined by Aaron Kelly of the University of Minnesota, Justin Ryder of Northwestern University, and Irl Hirsch, also of the University of Washington.

The immediate spark was specific and published: the scientists were handing out copies of an editorial published in Diabetes Care on April 29. Ars Technica reports the editorial “sharply” criticized the Trump administration's ongoing attacks on scientific research. The group was distributing those reprints outside a room where NIH director Jay Bhattacharya had been scheduled to speak. Instead of speaking as planned, Bhattacharya cancelled, and another NIH official spoke in his stead.

Then the meeting reportedly turned from awkward to alarming for the scientists involved. Kelly told MedPage Today, which first reported the incident, that “They physically grabbed us, forced us out of the conference center, and now are telling us we can no longer attend this meeting.” Kelly also said “They're taking our lanyards,” adding, “It really has come to this in America. Censorship is real. America needs to stand up. Scientists, stand up. Physicians, stand up.” In other words, what started as a distribution of an editorial inside an academic conference space became, according to the scientists, an enforced removal and restriction.

To understand why this matters beyond the conference doors, you have to look at how medical research ecosystems usually behave when politics enters the lab. Conferences like the ADA’s annual meeting are designed to be the meeting point of science, clinical practice, regulators, and funders. They are not just stagecraft for keynote speeches. They are where researchers network, where institutions signal legitimacy, and where leaders float ideas that may become funding priorities or policy direction later. When that normal flow is disrupted by enforcement actions, it changes behavior for everyone who’s trying to plan their careers, their collaborations, and their access.

The story also lands in the middle of a broader, ongoing tension between scientific institutions and government administrations over how research is governed and defended. The April 29 editorial in Diabetes Care is described as sharply critical of “ongoing attacks” on scientific research by the Trump administration. That kind of framing is not neutral. It is explicitly political, and it raises a question administrators and institutions often try to avoid: where does legitimate scientific dissent end, and where does it cross into activity conference security or event policy can treat as disruptive?

But the dispute here is not abstract. It took place at an ADA meeting in New Orleans, where the scientists handed out reprints outside the room where the NIH director was scheduled to speak. Then Bhattacharya cancelled his appearance, with “another NIH official” taking his place. That sequencing matters: it suggests the event team made a pivot around access and messaging, even before the reported physical removal. In fast-moving conference environments, “security” decisions often become catch-all solutions for reputational risk. Yet the scientists involved describe the outcome as censorship, not safety.

For executives, boards, and institutional leaders across healthcare, the second-order implications are uncomfortable. First, incidents like this can reshape how scientists interpret what is acceptable to do around policy figures, especially government officials like NIH leadership. If distribution of an editorial can trigger removal and lanyard confiscation, researchers may self-censor not because the science is weak, but because the operational cost of dissent becomes too high.

Second, it can pressure conference governance mechanisms, including how organizations craft rules for “disruption” versus “speech,” and how they train staff and security to enforce them. When enforcement is perceived as targeted at specific individuals, it can create a reputational feedback loop: more scrutiny, more media attention, and more skepticism about whether scientific events are open intellectual marketplaces or tightly managed messaging platforms.

Third, it can complicate the relationship between major journals and medical associations. Kahn is editor-in-chief of Diabetes Care, and the group was distributing a journal editorial. That links the incident directly to the credibility and authority of peer-reviewed publications. If academic content can trigger an enforced ejection when it is distributed in a particular context, universities, funders, and publishers have to think about how they protect academic freedom while still operating inside real-world event logistics.

Finally, there is the practical stake for anyone in the diabetes space and adjacent healthcare sectors: ADA is not just a conference brand. It is a central convening force in diabetes research and advocacy. If scientists believe they can be removed for circulating a specific editorial critical of government policy, the risk is not only personal embarrassment. It is a reduction in open debate at a time when clinical and research priorities depend on trust, transparency, and the ability to challenge policy when evidence is on the line. For leaders watching this unfold, the question is how to keep institutions open and credible under pressure, without letting enforcement decisions define the boundaries of scientific discussion.